Literature DB >> 27540135

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.

Maximilian Merz1, Hans Salwender2, Mathias Haenel3, Elias K Mai4, Uta Bertsch4,5, Christina Kunz6, Thomas Hielscher6, Igor W Blau7, Christof Scheid8, Dirk Hose4, Anja Seckinger4, Anna Jauch9, Jens Hillengass4, Marc S Raab4, Baerbel Schurich4, Markus Munder10, Peter Brossart11, Christian Gerecke12, Hans-Walter Lindemann13, Matthias Zeis14, Katja Weisel15, Jan Duerig16, Hartmut Goldschmidt4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27540135      PMCID： PMC5479613          DOI： 10.3324/haematol.2016.151266

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.

Authors:  María-Victoria Mateos; Sara Bringhen; Paul G Richardson; Juan Jose Lahuerta; Alessandra Larocca; Albert Oriol; Mario Boccadoro; Ramón García-Sanz; Francesco Di Raimondo; Dixie-Lee Esseltine; Helgi van de Velde; Avinash Desai; Anil Londhe; Jesús F San Miguel; Antonio Palumbo
Journal:  Haematologica       Date:  2014-04-24       Impact factor: 9.941

2.  Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.

Authors:  Murielle Roussel; Valérie Lauwers-Cances; Nelly Robillard; Cyrille Hulin; Xavier Leleu; Lotfi Benboubker; Gérald Marit; Philippe Moreau; Brigitte Pegourie; Denis Caillot; Christophe Fruchart; Anne-Marie Stoppa; Catherine Gentil; Soraya Wuilleme; Anne Huynh; Benjamin Hebraud; Jill Corre; Marie-Lorraine Chretien; Thierry Facon; Hervé Avet-Loiseau; Michel Attal
Journal:  J Clin Oncol       Date:  2014-07-14       Impact factor: 44.544

3.  Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain.

Authors:  Silvia Mangiacavalli; Alessandro Corso; Mara De Amici; Marzia Varettoni; Enrico Alfonsi; Alessandro Lozza; Mario Lazzarino
Journal:  Br J Haematol       Date:  2010-03-01       Impact factor: 6.998

4.  Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.

Authors:  Maximilian Merz; Hans Salwender; Mathias Haenel; Elias K Mai; Uta Bertsch; Christina Kunz; Thomas Hielscher; Igor W Blau; Christof Scheid; Dirk Hose; Anja Seckinger; Anna Jauch; Jens Hillengass; Marc S Raab; Baerbel Schurich; Markus Munder; Ingo G H Schmidt-Wolf; Christian Gerecke; Hans-Walter Lindemann; Matthias Zeis; Katja Weisel; Jan Duerig; Hartmut Goldschmidt
Journal:  Haematologica       Date:  2015-04-03       Impact factor: 9.941

5.  Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Authors:  Pieter Sonneveld; Ingo G H Schmidt-Wolf; Bronno van der Holt; Laila El Jarari; Uta Bertsch; Hans Salwender; Sonja Zweegman; Edo Vellenga; Annemiek Broyl; Igor W Blau; Katja C Weisel; Shulamiet Wittebol; Gerard M J Bos; Marian Stevens-Kroef; Christof Scheid; Michael Pfreundschuh; Dirk Hose; Anna Jauch; Helgi van der Velde; Reinier Raymakers; Martijn R Schaafsma; Marie-Jose Kersten; Marinus van Marwijk-Kooy; Ulrich Duehrsen; Walter Lindemann; Pierre W Wijermans; Henk M Lokhorst; Hartmut M Goldschmidt
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

6.  Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.

Authors:  Bertrand Arnulf; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Helgi van de Velde; Huaibao Feng; Andrew Cakana; William Deraedt; Philippe Moreau
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

Review 7.  Management of treatment-emergent peripheral neuropathy in multiple myeloma.

Authors:  P G Richardson; M Delforge; M Beksac; P Wen; J L Jongen; O Sezer; E Terpos; N Munshi; A Palumbo; S V Rajkumar; J L Harousseau; P Moreau; H Avet-Loiseau; J H Lee; M Cavo; G Merlini; P Voorhees; W J Chng; A Mazumder; S Usmani; H Einsele; R Comenzo; R Orlowski; D Vesole; J J Lahuerta; R Niesvizky; D Siegel; M-V Mateos; M Dimopoulos; S Lonial; S Jagannath; J Bladé; J San Miguel; G Morgan; K C Anderson; B G M Durie; P Sonneveld
Journal:  Leukemia       Date:  2011-12-23       Impact factor: 11.528

8.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Authors:  Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie-Lee Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau
Journal:  Lancet Oncol       Date:  2011-04-18       Impact factor: 41.316

9.  Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Joan Bladé; Mario Boccadoro; Jamie D Cavenagh; Anthony L Boral; Dixie-Lee Esseltine; Patrick Y Wen; Anthony A Amato; Kenneth C Anderson; Jesus San Miguel
Journal:  Br J Haematol       Date:  2009-01-16       Impact factor: 6.998

10.  Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

Authors:  Antonio Palumbo; Francesca Gay; Patrizia Falco; Claudia Crippa; Vittorio Montefusco; Francesca Patriarca; Fausto Rossini; Simona Caltagirone; Giulia Benevolo; Norbert Pescosta; Tommasina Guglielmelli; Sara Bringhen; Massimo Offidani; Nicola Giuliani; Maria Teresa Petrucci; Pellegrino Musto; Anna Marina Liberati; Giuseppe Rossi; Paolo Corradini; Mario Boccadoro
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544
View more
  4 in total

Review 1.  [Chemotherapy-induced peripheral neuropathy and neuropathic pain].

Authors:  U Schuler; S Heller
Journal:  Schmerz       Date:  2017-08       Impact factor: 1.107

2.  Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis.

Authors:  Shi-Dai Mu; Li-Sha Ai; You Qin; Yu Hu
Journal:  Curr Med Sci       Date:  2018-03-15

Review 3.  The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma.

Authors:  Maximilian Merz; Tobias Dechow; Mithun Scheytt; Christian Schmidt; Bjoern Hackanson; Stefan Knop
Journal:  Ann Hematol       Date:  2020-04-16       Impact factor: 3.673

4.  High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group.

Authors:  Iwona Hus; Joanna Mańko; Dariusz Jawniak; Artur Jurczyszyn; Grzegorz Charliński; Katarzyna Poniewierska-Jasak; Lidia Usnarska-Zubkiewicz; Mateusz Sawicki; Agnieszka Druzd-Sitek; Alina Świderska; Anna Kopińska; Norbert Grząśko; Małgorzata Raźny; Aleksandra Wędłowska; Aleksander Perzyński; Aleksandra Gałązka; Dominik Dytfeld; Tadeusz Kubicki; Marek Rodzaj; Anna Waszczuk-Gajda; Joanna Drozd-Sokołowska; Bartłomiej Pogłódek; Anna Pasternak; Monika Długosz-Danecka; Agnieszka Szymczyk; Anna Dmoszyńska
Journal:  Oncol Lett       Date:  2019-09-27       Impact factor: 2.967
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.